NEW YORK, NY, December 05, 2023 – PRISM MarketView, a leading provider of unbiased market insight and company news, highlights Altimmune, Inc. (Nasdaq: ALT) which has reported positive topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide. The company’s study enrolled 391 subjects with obesity and at least one comorbidity. Over 50% of subjects achieved at … Continue reading PRISM MARKETVIEW HIGHLIGHTS ALTIMMUNE’S POSITIVE TOPLINE RESULTS IN OBESITY DRUG TRIAL